コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 = 313), single (n = 89) or double (n = 123) umbilical cord blood.
2 r (nNIF) is an inhibitor of NET formation in umbilical cord blood.
3 mature/transitional 1 B cells recovered from umbilical cord blood.
4 ibly higher after transplants of HLA-matched umbilical cord blood.
5 ineage progenitor cells (MLPC) prepared from umbilical cord blood.
6 s and measurements of stem cell potential in umbilical cord blood.
7 al colony-forming cells (HPP-ECFCs) in human umbilical cord blood.
8 +) CD38(-) hematopoietic cells isolated from umbilical cord blood.
9 ancy and at delivery and in their infants in umbilical cord blood.
10 tioning and transplantation with human CD34+ umbilical cord blood.
11 man LAD2 and primary mast cells derived from umbilical cord blood.
12 progenitor cells (HSPCs) derived from human umbilical cord blood.
13 pairs, we analyzed natalizumab levels in the umbilical cord blood.
14 ritin levels were infant sex and ferritin in umbilical cord blood.
15 betes may have risk markers already in their umbilical cord blood.
16 d levels of thyroid hormones in maternal and umbilical-cord blood.
17 eripheral blood (61%), bone marrow (25%), or umbilical cord blood (14%); 53% were from unrelated dono
19 vailable clinical and biological advances of umbilical cord blood allogeneic stem cell transplantatio
21 Additional advances in the basic biology of umbilical cord blood also appear very promising in devel
22 s to collect biological specimens, including umbilical cord blood and amniotic fluid, to be made avai
23 -)CD7(-) human hematopoietic stem cells from umbilical cord blood and bone marrow were transplanted i
24 -mobilized CD34(+) cells isolated from human umbilical cord blood and demonstrate that MPO-induced ox
25 s) can be isolated from adult peripheral and umbilical cord blood and expanded exponentially ex vivo.
27 T cells are present in adult peripheral and umbilical cord blood and in both conventional T naive an
28 associated with stem cell potential in human umbilical cord blood and point to a potential mechanism
29 lood spots were slightly lower than those in umbilical cord blood and predicted umbilical cord blood
30 de methylation levels at 482,397 CpG loci in umbilical cord blood and retained 394,460 loci after qua
31 ations for blood-derived (from peripheral or umbilical cord blood) and bone marrow-derived stem cells
32 d RNA from fetuses with trisomies 21 and 18, umbilical cord blood, and blood from newborns with bronc
33 adult donor bone marrow, neonatal placental/umbilical cord blood, and mobilized adult donor peripher
34 human placenta and levels of its ligands in umbilical cord blood, and to verify the influence of Cxc
36 nors (URDs), either from volunteer adults or umbilical cord blood, are comparable with those from MSD
38 phenotypes, were compared with normal BM and umbilical cord blood as well as BM from children on enzy
39 mother's blood during the second trimester; umbilical cord blood at birth; and shed deciduous inciso
41 tion of human HSC (Lin-CD34+CD38-CD90+) from umbilical cord blood (CB) as well as the xenotransplanta
43 pluripotent stem cells (iPSCs) derived from umbilical cord blood (CB) cells and neonatal keratinocyt
44 higher in neonatal naive CD4(+) T cells from umbilical cord blood (CB) compared with naive CD4(+) T c
49 the development of NK cells after intrabone umbilical cord blood (CB) transplantation in 18 adult pa
50 he restricted numbers of stem cells found in umbilical cord blood (CB), while also enhancing the cont
52 ifferentiated in vitro from progenitors from umbilical cord blood (CB-EC) or adult peripheral blood (
53 roduces embryonic-like stem cells from human umbilical cord blood (CBEs) for neural differentiation u
54 -SLAM (not CD150(+)CD48(-)) cells from human umbilical cord blood CD34(+) cells as well as from human
57 NOD-scid/gammac(-/-) mice grafted with human umbilical cord blood CD34(+) hematopoietic progenitor ce
58 Cas9 genome engineering of primary adult and umbilical cord blood CD34(+) human hematopoietic stem an
59 ling and peroxiredoxin 4 expression in human umbilical cord blood cell-mediated protection of oligode
60 Transplantation of ex vivo expanded human umbilical cord blood cells (hCB) only partially enhances
61 In vivo, systemic administration of human umbilical cord blood cells 48 h after middle cerebral ar
63 s that delivery of circulating CD34(+) human umbilical cord blood cells can produce functional recove
64 that the soluble factors released from human umbilical cord blood cells converge on Akt to elevate pe
70 fold higher levels of engraftment with human umbilical-cord blood cells compared with NOD/LtSz-Rag1nu
71 Inverse associations between maternal or umbilical cord blood concentrations of perfluorooctanoic
72 cotinine level of 10 ng/mL or more and using umbilical cord blood cotinine as the criterion standard,
73 those in umbilical cord blood and predicted umbilical cord blood cotinine levels well (beta = 0.95,
75 al blood supplies are inadequate, allogeneic umbilical cord blood could be a feasible alternative.
77 use newborn blood (NBB), equivalent to human umbilical cord blood, could be used for diabetes prevent
78 rom adult tissues, including bone marrow and umbilical cord blood, could be utilized in repair and re
79 f Plasmodium falciparum malaria parasites in umbilical cord blood denotes infection acquired antenata
81 nd, a human immune system was generated from umbilical cord blood-derived CD34(+) hematopoietic stem
83 (IL-2), combined with ex vivo expanded human umbilical cord blood-derived CD8(+) T cells, that have b
87 d vessels generated by peripheral blood- and umbilical cord blood-derived EPCs in a model of in vivo
89 In this study, we genetically modified human umbilical cord blood-derived hematopoietic stem cells (H
90 f AHR results in a marked expansion of human umbilical cord blood-derived HSPCs following cytokine st
93 imulates human leukemic mast cells and human umbilical cord blood-derived mast cells to release newly
100 (RIC) was used with either unrelated double umbilical cord blood (dUCB) or HLA-haploidentical relate
104 Unstimulated human mast cells derived from umbilical cord blood express the immunoreceptor tyrosine
105 numbers of CD34(+) cells isolated from human umbilical cord blood, for therapeutic applications.
106 ELISA was used to quantify beta(2)GPI in umbilical cord blood from 97 neonates exposed to anti-Ro
107 rabbe's disease underwent transplantation of umbilical-cord blood from unrelated donors after myeloab
108 We hypothesized that transplantation of umbilical-cord blood from unrelated donors before the de
112 shown that NKG2C(+) NK cells from CMV naive umbilical cord blood grafts expand preferentially in rec
113 h T cell-depleted or naive T cell-containing umbilical cord blood grafts, suggesting a role for T cel
115 suggest that techniques for bone marrow and umbilical cord blood harvest may benefit from means to d
117 ne marrow or peripheral blood, or the use of umbilical cord blood, has decreased the risk of graft-ve
118 Transplantation of bone marrow cells and umbilical cord blood have been attempted as a means of e
119 ) isolated from sites such as bone marrow or umbilical cord blood have been the primary means to iden
120 e and neck 28 days after undergoing a double umbilical cord blood hematopoietic stem cell transplant
121 th her newborn sibling donor's HLA-identical umbilical cord blood hematopoietic stem cells (HSCs).
122 eripheral blood mononuclear cells (PBMC) and umbilical-cord blood hematopoietic progenitor cells was
123 and contrasting with what was observed with umbilical cord blood HPCs, CD34(+) HPCs from human adult
126 laboratory has shown that infusion of human umbilical cord blood (HUCB) cells protects striatal whit
127 ince the first successful transplantation of umbilical cord blood in 1988, cord blood has become an i
128 tched and one- or two-antigen HLA-mismatched umbilical cord blood in children with acute leukaemia wh
135 s were lower among 13 participants with high umbilical cord blood lead concentrations (>/= 10 mug/dL)
136 ter (aerodynamic diameter </=2.5 microm) and umbilical cord blood leptin and adiponectin levels with
138 hic characteristics and further adjusted for umbilical cord blood mercury or long-chain polyunsaturat
139 Median (25th-75th percentile) maternal and umbilical cord blood metal concentrations, respectively,
140 val was similar to that after transplants of umbilical cord blood mismatched for either one or two an
141 ally sufficient mononuclear cells from human umbilical cord blood (MNC hUCB) were intravenously admin
145 T cells from both adult peripheral blood and umbilical cord blood mononuclear cells constitutively ex
146 HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)
147 son, human BM HDODs-, healthy donor-derived, umbilical cord blood nuclear cells, or CD34(+) cells wer
148 posure and epigenome-wide DNA methylation in umbilical cord blood nucleated cells in Project Viva, a
149 ncentrations of adalimumab and infliximab in umbilical cord blood of newborns and rates of clearance
151 lower-brominated PBDEs were often higher in umbilical cord blood or serum than in maternal samples (
152 ll have a suitable alternative using an URD, umbilical cord blood, or haploidentical-related donors;
153 nd gamma-CEHC concentrations in maternal and umbilical cord blood pairs and examined their relations
155 acking a suitable family or unrelated donor, umbilical cord blood provides a promising alternative gr
157 ude that identification of preformed DSAs in umbilical cord blood recipients should be performed and
158 er transplants of two-antigen HLA-mismatched umbilical cord blood (relative risk 2.31, p=0.0003) and
162 rmful chemicals in 77 maternal and 65 paired umbilical cord blood samples collected in San Francisco
163 cell mass cytometry of paired peripheral and umbilical cord blood samples from mothers and their neon
164 timated in 282 school-age children from whom umbilical cord blood samples had been obtained and analy
167 luated by testing paired maternal plasma and umbilical cord blood samples, as well as newborn whole-b
170 d donors, haploidentical related donors, and umbilical cord blood stem cell products are frequently u
172 Cell has demonstrated dramatic expansion of umbilical cord blood stem cells that promote rapid engra
173 (+) and CD4(+)CD161(-) naive Th subsets from umbilical cord blood surprisingly revealed comparable hy
175 nine levels in dried blood spots to those in umbilical cord blood to assess cotinine in dried blood s
176 re evolution, analyzing samples ranging from umbilical cord blood to centenarian peripheral blood.
177 f of principle for the utility of allogeneic umbilical cord blood transfusion to treat patients with
178 A 12-month-old boy underwent unrelated donor umbilical cord blood transplant (UCBT) for refractory La
181 ection was significantly more frequent after umbilical cord blood transplant and was associated with
185 cell alloreactivity is favored after double umbilical cord blood transplantation (dUCBT) in which co
186 virus 6B (HHV-6B) commonly reactivates after umbilical cord blood transplantation (UCBT) and is assoc
187 r transplantation (MMRDT) or unrelated-donor umbilical cord blood transplantation (UCBT) are valuable
188 he state of the art of unrelated donor (URD) umbilical cord blood transplantation (UCBT) for the trea
196 , 31 patients with Hurler syndrome underwent umbilical cord blood transplantation and were evaluated
197 such as the marrow failure that occurs after umbilical cord blood transplantation and with aplastic a
198 with metachromatic leukodystrophy underwent umbilical cord blood transplantation at different stages
199 eeply influence NK cell reconstitution after umbilical cord blood transplantation by accelerating the
201 evel HLA matching who received a single unit umbilical cord blood transplantation for non-malignant d
202 tients with hematological malignancies given umbilical cord blood transplantation from donors carryin
207 ernational studies suggested that allogeneic umbilical cord blood transplantation may potentially eme
210 s may reduce graft-versus-host disease after umbilical cord blood transplantation, but this naivety a
212 New investigations include MSC infusions in umbilical cord blood transplantation, MSC therapy for ti
222 e risk of transplant-related mortality after umbilical-cord-blood transplantation, greater investment
224 a retrospective single-center analysis of 50 umbilical cord blood transplantations UCBTs performed fr
226 recipient HLA matching on outcomes of single umbilical-cord blood transplantations for leukaemia and
230 compared the NK responses to influenza using umbilical cord blood (UCB) and adult peripheral blood (A
231 oning (RIC) and transplantation of unrelated umbilical cord blood (UCB) and CD34(+) stem cells from a
232 rks the 20th anniversary of the first use of umbilical cord blood (UCB) as a source of donor cells fo
234 We have purified primitive HSCs from human umbilical cord blood (UCB) by lineage depletion (Lin(-))
235 ptosis and suppressor cell function of human umbilical cord blood (UCB) CD4+25+ Treg and CD4+25- cell
239 of single (n = 91) or double (n = 166) unit umbilical cord blood (UCB) grafts after myeloablative (n
246 r, knowledge as to whether FLG expression in umbilical cord blood (UCB) is associated with eczema dev
252 rgoing in vitro differentiation from CD34(+) umbilical cord blood (UCB) progenitors, LFA-1 expression
255 nderlying the blunted allo-responsiveness of umbilical cord blood (UCB) T cells have not been fully e
257 and progenitors reside within a fraction of umbilical cord blood (UCB) that exhibits low light scatt
258 discuss the recent advances in the field of umbilical cord blood (UCB) transplant (UCBT) for the tre
266 en (HLA)-A, -B, -C, and -DRB1 in 1568 single umbilical cord blood (UCB) transplantations for hematolo
268 or registries of adult volunteers and banked umbilical cord blood (UCB) units provide the potential f
270 mary human T cells from adult peripheral and umbilical cord blood (UCB), thymus and tonsil, although
272 or of activated T cells-1 (NFAT1) protein in umbilical cord blood (UCB)-derived CD4+ T cells and the
273 d clinical outcomes of patients treated with umbilical cord blood (UCB)-derived regulatory T cells (T
277 ntensity conditioning using either unrelated umbilical-cord blood (UCB) or matched-sibling donors (MS
278 r data suggest that the present strategy for umbilical-cord blood unit selection should be reassessed
279 eport the relative efficacy of co-infusing 2 umbilical cord blood units (dUCB) compared with peripher
280 yte antigen match and with the use of double umbilical cord blood units and improved supportive care
281 umbilical cord blood transplantation, double umbilical cord blood units and nonmyeloablative engraftm
283 rent practice in that selection of unrelated umbilical cord blood units for transplantation for non-m
284 en comparing patients with DSAs against both umbilical cord blood units to those without DSAs (3-year
285 ents should be performed and that the use of umbilical cord blood units where preformed host DSAs exi
286 or registries of adult volunteers and banked umbilical cord-blood units, such as the Be the Match Reg
292 engraftment of hematopoietic stem cells from umbilical-cord blood, we observed a new syndrome of cult
293 ) with acute leukaemia and transplanted with umbilical cord blood were compared with outcomes of 282
294 king, mononuclear cells harvested from human umbilical cord blood were grown under proendothelial con
295 ith partially HLA-mismatched unrelated donor umbilical cord blood were studied to investigate the imp
298 dren (upper tertile of CPF concentrations in umbilical cord blood) were compared with 20 low-exposure
299 fficiency of nonsense-mediated mRNA decay in umbilical cord blood, which may reflect specific regulat
300 n of caffeine and its primary metabolites in umbilical cord blood with intrauterine growth restrictio
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。